Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation
Article first published online: 1 OCT 2012
© Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 13, Issue 1, pages 100–110, January 2013
How to Cite
Isakova, T., Xie, H., Messinger, S., Cortazar, F., Scialla, J. J., Guerra, G., Contreras, G., Roth, D., Burke, G. W., Molnar, M. Z., Mucsi, I. and Wolf, M. (2013), Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation. American Journal of Transplantation, 13: 100–110. doi: 10.1111/j.1600-6143.2012.04281.x
- Issue published online: 26 DEC 2012
- Article first published online: 1 OCT 2012
- Manuscript Accepted: 19 AUG 2012
- Manuscript Revised: 10 AUG 2012
- Manuscript Received: 3 JUL 2012
- NIH. Grant Numbers: K23DK087858, R01DK076116, R01DK081374
- Health Resources and Services Administration. Grant Number: 234-2005-37011C
- Transplantation 50 years later—progress, challenges, and promises. N Engl J Med 2004; 351: 2761–2766. , .
- Rejection of the kidney allograft. N Engl J Med 2010; 363: 1451–1462. , .
- Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715–2729. .
- Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999; 68: 1526–1532. , , , , .
- A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271–280. .
- Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. The Rapamune US study group. Lancet 2000; 356: 194–202. .
- Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436–442. , , , et al.
- Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777–786. , , , , , .
- Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562–2575. , , , et al.
- The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633–1644. , , , et al.
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet 2011; 377: 837–847. , , , et al.
- Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. Am J Transplant 2012; 12: 379–387. , , , et al.
- Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. J Am Soc Nephrol 2011; 22: 743–751. , , , , .
- Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515–526. , .
- Analyses of the UNOS Scientific Renal Transplant Registry at three years—early events affecting transplant success. Transplantation 1992; 53: 59–64. , , .
- Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993; 55: 993–995. , , , et al.
- Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution—a simulation study. Am J Epidemiol 2010; 172: 843–854. , , , .
- Analysis of clustered matched-pair data. Stat Med 2003; 22: 2417–2428. , , , .
- The Wilcoxon signed rank test for paired comparisons of clustered data. Biometrics 2006; 62: 185–192. , , .
- Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234–1248. , , , .
- Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410–418. , , , et al.
- Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol 2011; 22: 1758–1768. , , , et al.
- Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876–1885. , , , et al.
- Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant 2012; 12: 694–705. , , , et al.
- Information for Healthcare Professionals: Sirolimus (marketed as Rapamune). FDA ALERT [06/11/2009]. Available at: http://wwwfdagov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165015htm. Accessed April 3, 2012.
- Sirolimus conversion for renal dysfunction in liver transplant recipients: The devil really is in the details. Am J Transplant 2012; 12: 521–522. , .
- Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586–594. , , , , , .
- Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 2003; 158: 915–920. .
- Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329–339. , , , et al.
- Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198–1203. , , , , .
- Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384–1392. , , , et al.
- Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transplant Int 2011; 24: 1216–1230. , , .
- Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009; 88: 1010–1018. , , , et al.
- COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–1073. , , , , , .
- Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 2003; 26: 2983–2989. , , , , .
- Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601–2614. .
- Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985–992. .
- Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891–1901. , , , et al.